JAB-2485

N/A

Report date: 2024/07/11 14:15:58
NME

Base Information

Drug NameJAB-2485
Drug Alias NameJAB-2485
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Aurora-A inhibitors
TargetsSerine/threonine-protein kinase Aurora-A
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJacobio Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJacobio Pharmaceuticals Group Co LtdJacobio Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A